文献速递其他结缔组织病

抗MDA5抗体阳性皮肌炎的难治性皮肤溃疡与快速进展型间质性肺病无关,且对他达拉非治疗有反应

Refractory cutaneous ulcers in anti-MDA5 dermatomyositis were not associated with rapidly progressive interstitial lung disease, and responded to tadalafil.
PubMed 文献 · Semin Arthritis Rheum · 2025-01-31

回顾性分析82例抗MDA5抗体阳性皮肌炎患者,26例(31.7%)有皮肤溃疡,其中10例(38.5%)为难治性皮肤溃疡;单因素分析显示溃疡患者更易出现Gottron征、甲周红斑和关节炎,而非溃疡患者更易出现运动后气短和快速进展型间质性肺病。加用他达拉非后,8例(80%)在1至2个月内医生整体评估、CDASI评分和患者疼痛VAS评分改善,5例溃疡完全愈合。结论认为抗MDA5皮肌炎的溃疡性皮疹可能与快速进展型间质性肺病无关,他达拉非可能是有用的治疗。

要点

  • 抗MDA5抗体阳性皮肌炎患者中31.7%(26/82)出现皮肤溃疡,其中38.5%(10/26)为难治性皮肤溃疡。
  • 溃疡患者更易有Gottron征(p=0.026)、甲周红斑(p=0.007)和关节炎(p=0.031)。
  • 加用他达拉非后80%(8/10)难治性溃疡患者PGA、CDASI和p-VAS改善,5例完全愈合。

核心结论

  • 抗MDA5抗体阳性皮肌炎的溃疡性皮疹可能与快速进展型间质性肺病无关。
  • 他达拉非可能对难治性皮肤溃疡是有用的治疗。

研究设计与样本

  • 回顾性分析82例连续抗MDA5抗体阳性皮肌炎患者的病历资料,收集皮疹、影像学特征和血清标志物数据。
  • 对其中接受他达拉非治疗的难治性皮肤溃疡患者进行回顾性分析。

主要发现

  • 82例抗MDA5抗体阳性皮肌炎患者中62例(75.6%)为女性,约95.0%有间质性肺病,45.1%有快速进展型间质性肺病。
  • 所有患者(100%)有典型皮疹,包括Gottron征(87.8%)、向阳疹(69.5%)和枪套征(24.4%)。
  • 26例(31.7%)有皮肤溃疡,其中10例(38.5%)为难治性皮肤溃疡,包括5例男性。
  • 单因素分析显示溃疡患者易出现Gottron征(p=0.026)、甲周红斑(p=0.007)和关节炎(p=0.031),而非溃疡患者更易出现运动后气短(p=0.027)和快速进展型间质性肺病(p=0.024)。
  • 加用他达拉非后,8例(80%)患者在1至2个月内PGA、CDASI评分和p-VAS疼痛评分改善,5例难治性皮肤溃疡完全消退。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The purpose of this study was to analyze the characteristics of an ulcerative rash in dermatomyositis (DM) patients with anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody and to assess the efficacy of tadalafil in the management of refractory cutaneous ulcers. METHODS: Medical records of DM patients with anti-MDA5 antibody were reviewed. Skin rash data, radiologic characteristic and serum markers were collected. Patients with refractory cutaneous ulcers treated with tadalafil were reviewed retrospectively. RESULTS: Eighty-two consecutive cases with anti-MDA5-antibody positive DM (anti-MDA5 DM) were identified, including 62 (75.6 %) female patients. Approximately 95.0 % of the patients had interstitial lung disease (ILD) and 45.1 % had rapidly progressive ILD (RP-ILD). All patients (100 %) had typical skin rashes, such as Gottron's sign (87.8 %), heliotrope sign (69.5 %), and the holster sign (24.4 %). Twenty-six patients (31.7 %) had cutaneous ulcers. Univariate analysis showed that ulcer patients were prone to Gottron's sign (p = 0.026), perlungual erythematosus (p = 0.007), and arthritis (p = 0.031), while shortness of breath after exercise (p = 0.027) and RP-ILD (p = 0.024) are more likely to appear in patients with non-skin ulcers. Among the anti-MDA5 DM patients with skin ulcers, 10 (38.5 %) were refractory cutaneous ulcers, including five male patients. After tadalafil was added, eight (80 %) patients showed improvement in the physician global assessment (PGA), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) score and the patient's pain score using the visual analog score (p-VAS), within one to two months. In addition, the refractory cutaneous ulcers of five patients completely resolved after treatment. CONCLUSIONS: This study found that ulcerative rash in anti-MDA5 DM may not be associated with RP-ILD. The results also suggest that tadalafil may be a useful therapy for refractory cutaneous ulcers.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ge Y, Jiang W, Lu X, et al. Refractory cutaneous ulcers in anti-MDA5 dermatomyositis were not associated with rapidly progressive interstitial lung disease, and responded to tadalafil. Semin Arthritis Rheum. 2025. PMID: 39914261. doi:10.1016/j.semarthrit.2025.152651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。